Clinical Trial Update: Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial comparing safety and pharmacokinetic characteristics of Daewoong's DWP422 biosimilar to Enbrel (etanercept) in healthy male volunteers, with relev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• DWP422 (etanercept)
• ENBREL (etanercept)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Rheumatoid Arthritis | Phase 1 | Status: UNKNOWN